The most recent data from the Canadian CF Registry 2022 has confirmed this continued trend [55] and the latest clinical data from combination CFTR modulator therapy, elexacaftor/tezacaftor/ivacaftor still show worse pulmonary exacerbations in female CF patients compared to males, despite greatly improved lung function in both sexes [56]. The gene discussed is CFTR; the disease is cystic fibrosis.